Back
  • There are no suggestions because the search field is empty.

Clinical solutions

Integrated AI pathology – fast, precise, proven

Aiforia® Clinical Suites deliver integrated workflows to enhance efficiency, consistency, and diagnostic accuracy. Users can leverage AI-driven image analysis, standardized scoring, and automated reporting to achieve objective, quantitative, and explainable results. Proven in clinical settings worldwide, Aiforia integrates into existing workflows with flexible deployment options, empowering pathology laboratories to handle the growing case volumes.

Request a demo

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Gastric Cancer Lymph Node Metastasis

Breast Cancer Suite

Aiforia® Breast Cancer Grading
Aiforia® Breast Cancer ER
Aiforia® Breast Cancer PR
Aiforia® Breast Cancer HER2
Aiforia® Breast Cancer Ki67
Aiforia® Lymph Node Metastasis
breast-cancer-grading_image 1

Automates breast cancer grading from H&E-stained whole-slide images (WSI), accurately identifying invasive carcinoma and ductal carcinoma in situ (DCIS). It objectively scores mitotic count, tubular formation, and nuclear pleomorphism, addressing key challenges of manual grading such as variability and time constraints, consistent with the Nottingham Grading System. 

Clinical performance highlights
  • Substantially reduces grading time (50% faster)
  • High correlation with expert grading assessments
  • Consistently reproducible, reducing interobserver variability


CE-IVD marked for diagnostic use in EU and EEA countries (IVDR) and for Research Use Only (RUO) and Performance Studies Only (PSO) in all other market areas

 

Breast ER with AI masks

Automatically detects invasive carcinoma and quantifies ER-positive and negative tumor cells from whole-slide images (WSI) or selected tissue areas, supporting consistent and objective scoring.

Clinical performance highlights
  • Exceptional diagnostic accuracy with high correlation to expert assessments
  • Improved diagnostic consistency with reduced interobserver variability
  • Accelerated workflow with up to 47% faster ER scoring


CE-IVD marked for diagnostic use in EU and EEA countries, and for Research Use Only (RUO) and Performance Studies Only (PSO) in all other market areas

Breast PR with AI masks

Automatically detects invasive carcinoma and quantifies PR-positive and negative cells from whole-slide images (WSI) or selected tissue regions, enhancing diagnostic clarity and workflow.

Clinical performance highlights
  • High diagnostic confidence with enhanced interobserver agreement
  • Reliable reproducibility with near-perfect consistency
  • Efficient workflow with approximately 12% faster scoring


CE-IVD marked for diagnostic use in EU and EEA countries, and for Research Use Only (RUO) and Performance Studies Only (PSO) in all other market areas

BrCa_HER2_20x_cropped

Accurately identifies invasive carcinoma and scores HER2 expression in alignment with CAP guidelines,  improving diagnostic reliability and workflow efficiency.

Clinical performance highlights
  • Outstanding sensitivity and precision for confident HER2 classification
  • Enhanced diagnostic consistency with increased interobserver concordance
  • Objective support to identify challenging HER2-low and HER2-ultralow cases


CE-IVD marked for diagnostic use in EU and EEA countries (IVDR) and for Research Use Only (RUO) and Performance Studies Only (PSO) in all other market areas

Breast Ki67 with AI masks

Automatically detects invasive carcinoma and quantifies Ki67-positive and negative tumor cells from whole-slide images (WSI) or targeted image regions, improving diagnostic accuracy and workflow.

Clinical performance highlights
  • High diagnostic accuracy with excellent correlation to expert visual scoring
  • Enhanced diagnostic concordance through improved pathologist agreement
  • Significant time savings, reducing scoring duration by up to 54%
  • Reliable precision with automated hotspot detection for accurate proliferation assessment

CE-IVD marked for diagnostic use in EU and EEA countries, and for Research Use Only (RUO) and Performance Studies Only (PSO) in all other market areas

aiforia-lymph-node-metastasis-breast

Supports the detection and quantification of metastases of breast cancer in lymph nodes from whole slide images.

Clinical performance highlights
  • Showed excellent correlation with visual diagnosis
  • Saved time (up to 40% faster)

Aiforia® Lymph Node Metastasis is currently for Research Use Only (RUO) and for Performance Studies Only (PSO) in all market areas. 

Breast Cancer Suite

Aiforia® Breast Cancer Grading

breast-cancer-grading_image 1

Automates breast cancer grading from H&E-stained whole-slide images (WSI), accurately identifying invasive carcinoma and ductal carcinoma in situ (DCIS). It objectively scores mitotic count, tubular formation, and nuclear pleomorphism, addressing key challenges of manual grading such as variability and time constraints, consistent with the Nottingham Grading System. 

Clinical performance highlights
  • Substantially reduces grading time (50% faster)
  • High correlation with expert grading assessments
  • Consistently reproducible, reducing interobserver variability


CE-IVD marked for diagnostic use in EU and EEA countries (IVDR) and for Research Use Only (RUO) and Performance Studies Only (PSO) in all other market areas

 

Aiforia® Breast Cancer ER

Breast ER with AI masks

Automatically detects invasive carcinoma and quantifies ER-positive and negative tumor cells from whole-slide images (WSI) or selected tissue areas, supporting consistent and objective scoring.

Clinical performance highlights
  • Exceptional diagnostic accuracy with high correlation to expert assessments
  • Improved diagnostic consistency with reduced interobserver variability
  • Accelerated workflow with up to 47% faster ER scoring


CE-IVD marked for diagnostic use in EU and EEA countries, and for Research Use Only (RUO) and Performance Studies Only (PSO) in all other market areas

Aiforia® Breast Cancer PR

Breast PR with AI masks

Automatically detects invasive carcinoma and quantifies PR-positive and negative cells from whole-slide images (WSI) or selected tissue regions, enhancing diagnostic clarity and workflow.

Clinical performance highlights
  • High diagnostic confidence with enhanced interobserver agreement
  • Reliable reproducibility with near-perfect consistency
  • Efficient workflow with approximately 12% faster scoring


CE-IVD marked for diagnostic use in EU and EEA countries, and for Research Use Only (RUO) and Performance Studies Only (PSO) in all other market areas

Aiforia® Breast Cancer HER2

BrCa_HER2_20x_cropped

Accurately identifies invasive carcinoma and scores HER2 expression in alignment with CAP guidelines,  improving diagnostic reliability and workflow efficiency.

Clinical performance highlights
  • Outstanding sensitivity and precision for confident HER2 classification
  • Enhanced diagnostic consistency with increased interobserver concordance
  • Objective support to identify challenging HER2-low and HER2-ultralow cases


CE-IVD marked for diagnostic use in EU and EEA countries (IVDR) and for Research Use Only (RUO) and Performance Studies Only (PSO) in all other market areas

Aiforia® Breast Cancer Ki67

Breast Ki67 with AI masks

Automatically detects invasive carcinoma and quantifies Ki67-positive and negative tumor cells from whole-slide images (WSI) or targeted image regions, improving diagnostic accuracy and workflow.

Clinical performance highlights
  • High diagnostic accuracy with excellent correlation to expert visual scoring
  • Enhanced diagnostic concordance through improved pathologist agreement
  • Significant time savings, reducing scoring duration by up to 54%
  • Reliable precision with automated hotspot detection for accurate proliferation assessment

CE-IVD marked for diagnostic use in EU and EEA countries, and for Research Use Only (RUO) and Performance Studies Only (PSO) in all other market areas

Aiforia® Lymph Node Metastasis

aiforia-lymph-node-metastasis-breast

Supports the detection and quantification of metastases of breast cancer in lymph nodes from whole slide images.

Clinical performance highlights
  • Showed excellent correlation with visual diagnosis
  • Saved time (up to 40% faster)

Aiforia® Lymph Node Metastasis is currently for Research Use Only (RUO) and for Performance Studies Only (PSO) in all market areas. 

AI for breast cancer diagnostics

Aiforia® Breast Cancer Suite offers a fully digital cockpit for breast cancer diagnostics, supporting the entire diagnostic workflow.

Find out more

Lung Cancer Suite

Aiforia® Lung Cancer PD-L1
Lung PD-L1 with AI masks

Automatically detects invasive carcinoma and delivers standardized, reproducible TPS scoring, enhancing diagnostic accuracy and efficiency. It assists pathologists in overcoming the challenges of subjective and time-consuming manual PD-L1 scoring in lung cancer.

Clinical performance highlights
  • Excellent diagnostic accuracy with high correlation to expert visual assessments
  • Enhanced consistency through improved pathologist concordance (Fleiss’ Kappa ~0.87)
  • Significantly streamlined workflow, reducing analysis time by up to 46%
  • Reliable and standardized scoring at critical clinical thresholds (e.g., 1% and 50%)


CE-IVD marked for diagnostic use in EU and EEA countries, and for Research Use Only (RUO) and Performance Studies Only (PSO) in all other market areas

Lung Cancer Suite

Aiforia® Lung Cancer PD-L1

Lung PD-L1 with AI masks

Automatically detects invasive carcinoma and delivers standardized, reproducible TPS scoring, enhancing diagnostic accuracy and efficiency. It assists pathologists in overcoming the challenges of subjective and time-consuming manual PD-L1 scoring in lung cancer.

Clinical performance highlights
  • Excellent diagnostic accuracy with high correlation to expert visual assessments
  • Enhanced consistency through improved pathologist concordance (Fleiss’ Kappa ~0.87)
  • Significantly streamlined workflow, reducing analysis time by up to 46%
  • Reliable and standardized scoring at critical clinical thresholds (e.g., 1% and 50%)


CE-IVD marked for diagnostic use in EU and EEA countries, and for Research Use Only (RUO) and Performance Studies Only (PSO) in all other market areas

Prostate Cancer Suite

Aiforia® Prostate Cancer Gleason Grade Groups
Aiforia® Prostate Cancer PNI
Aiforia® Prostate Cancer G4 Cribriform
Aiforia® Prostate Cancer HG-PIN
Prostate_20x_AImasks_cropped

Automatically identifies adenocarcinoma, streamlines the Gleason grading process, and directly addresses interobserver variability and subtle pattern detection challenges commonly faced by pathologists.

Clinical performance highlights
  • Exceptional diagnostic accuracy with excellent correlation to expert grading
  • Improved reproducibility and reduced interobserver variability
  • Significantly faster Gleason scoring, saving up to 34% of analysis time


CE-IVD marked for diagnostic use in EU and EEA countries, and for Research Use Only (RUO) and Performance Studies Only (PSO) in all other market areas

PNI 40x all masks-1

Efficiently detects subtle perineural invasion (PNI) features, addressing the common diagnostic challenge of accurately and consistently identifying tumor involvement around nerves.

Clinical performance highlights
  • High diagnostic confidence with excellent correlation to visual assessments
  • Improved reproducibility, ensuring reliable identification of subtle PNI
  • Enhanced workflow efficiency with scoring times reduced by up to 29%


CE-IVD marked for diagnostic use in EU and EEA countries (IVDR) and for Research Use Only (RUO) and Performance Studies Only (PSO) in all other market areas

G4 crib 20x adv mask only-1

Automatically detects Gleason Grade 4 Cribriform patterns in prostate biopsy whole slide images (WSI), addressing pathologists' challenges with subjective, time-consuming visual assessments, with the aim to reduce diagnostic variability and enhance workflow efficiency.

Clinical performance highlights
  • Excellent diagnostic reliability, consistently aligning with expert visual assessments
  • Improved reproducibility and reduced diagnostic variability
  • Significantly reduced analysis time, improving workflow by up to 54%


CE-IVD marked for diagnostic use in EU and EEA countries (IVDR) and for Research Use Only (RUO) and Performance Studies Only (PSO) in all other market areas

HGPIN 40x adv mask only-1

Supports the detection of high-grade prostatic intraepithelial neoplasia (high-grade PIN) in whole slide images (WSI) of prostate tissue. 


Aiforia® Prostate Cancer HG-PIN is currently for Research Use Only (RUO) and for Performance Studies Only (PSO) in all market areas. 

Prostate Cancer Suite

Aiforia® Prostate Cancer Gleason Grade Groups

Prostate_20x_AImasks_cropped

Automatically identifies adenocarcinoma, streamlines the Gleason grading process, and directly addresses interobserver variability and subtle pattern detection challenges commonly faced by pathologists.

Clinical performance highlights
  • Exceptional diagnostic accuracy with excellent correlation to expert grading
  • Improved reproducibility and reduced interobserver variability
  • Significantly faster Gleason scoring, saving up to 34% of analysis time


CE-IVD marked for diagnostic use in EU and EEA countries, and for Research Use Only (RUO) and Performance Studies Only (PSO) in all other market areas

Aiforia® Prostate Cancer PNI

PNI 40x all masks-1

Efficiently detects subtle perineural invasion (PNI) features, addressing the common diagnostic challenge of accurately and consistently identifying tumor involvement around nerves.

Clinical performance highlights
  • High diagnostic confidence with excellent correlation to visual assessments
  • Improved reproducibility, ensuring reliable identification of subtle PNI
  • Enhanced workflow efficiency with scoring times reduced by up to 29%


CE-IVD marked for diagnostic use in EU and EEA countries (IVDR) and for Research Use Only (RUO) and Performance Studies Only (PSO) in all other market areas

Aiforia® Prostate Cancer G4 Cribriform

G4 crib 20x adv mask only-1

Automatically detects Gleason Grade 4 Cribriform patterns in prostate biopsy whole slide images (WSI), addressing pathologists' challenges with subjective, time-consuming visual assessments, with the aim to reduce diagnostic variability and enhance workflow efficiency.

Clinical performance highlights
  • Excellent diagnostic reliability, consistently aligning with expert visual assessments
  • Improved reproducibility and reduced diagnostic variability
  • Significantly reduced analysis time, improving workflow by up to 54%


CE-IVD marked for diagnostic use in EU and EEA countries (IVDR) and for Research Use Only (RUO) and Performance Studies Only (PSO) in all other market areas

Aiforia® Prostate Cancer HG-PIN

HGPIN 40x adv mask only-1

Supports the detection of high-grade prostatic intraepithelial neoplasia (high-grade PIN) in whole slide images (WSI) of prostate tissue. 


Aiforia® Prostate Cancer HG-PIN is currently for Research Use Only (RUO) and for Performance Studies Only (PSO) in all market areas. 

AI for prostate cancer diagnostics

Aiforia® Prostate Cancer Suite consists of AI models with an optimized interactive user interface that supports pathologists in Gleason grade grouping and identifying adverse histopathological features.

Find out more

Colon Suite

Aiforia® Colorectal Cancer QuantCRC
Aiforia® Lymph Node Metastasis
QuantCRC_image

Identifies important histological features of colorectal cancer and provides a recurrence prediction estimate useful for treatment decisions. This prognostic AI model was developed and validated in collaboration with the Mayo Clinic.

Clinical performance highlights
  • Verified and validated in the Aiforia® Platform using whole slide images from eight independent hospitals and patient cohorts
  • Improved risk stratification as compared to the American Society of Clinical Oncology staging


Aiforia® Colorectal Cancer QuantCRC is currently for Research Use Only (RUO) and for Performance Studies Only (PSO) in all market areas.

Learn more

aiforia-lymph-node-metastasis

Supports the detection and quantification of metastases of colorectal cancer in lymph nodes from whole slide images. The AI model was developed in collaboration with the University of Bern.

Clinical performance highlights
  • Showed excellent correlation with visual diagnosis
  • Saved time (up to 40% faster)

Aiforia® Lymph Node Metastasis is currently for Research Use Only (RUO) and for Performance Studies Only (PSO) in all market areas.

Colon Suite

Aiforia® Colorectal Cancer QuantCRC

QuantCRC_image

Identifies important histological features of colorectal cancer and provides a recurrence prediction estimate useful for treatment decisions. This prognostic AI model was developed and validated in collaboration with the Mayo Clinic.

Clinical performance highlights
  • Verified and validated in the Aiforia® Platform using whole slide images from eight independent hospitals and patient cohorts
  • Improved risk stratification as compared to the American Society of Clinical Oncology staging


Aiforia® Colorectal Cancer QuantCRC is currently for Research Use Only (RUO) and for Performance Studies Only (PSO) in all market areas.

Learn more

Aiforia® Lymph Node Metastasis

aiforia-lymph-node-metastasis

Supports the detection and quantification of metastases of colorectal cancer in lymph nodes from whole slide images. The AI model was developed in collaboration with the University of Bern.

Clinical performance highlights
  • Showed excellent correlation with visual diagnosis
  • Saved time (up to 40% faster)

Aiforia® Lymph Node Metastasis is currently for Research Use Only (RUO) and for Performance Studies Only (PSO) in all market areas.

Gastric Suite

Aiforia® Gastric Cancer
Gastric and H pylori

Supports the detection of gastric cancer and Helicobacter pylori in whole slide images (WSI) of H&E-stained FFPE gastric tissue.


Aiforia® Gastric Cancer is currently for Research Use Only (RUO) and for Performance Studies Only (PSO) in all market areas.

Gastric Suite

Aiforia® Gastric Cancer

Gastric and H pylori

Supports the detection of gastric cancer and Helicobacter pylori in whole slide images (WSI) of H&E-stained FFPE gastric tissue.


Aiforia® Gastric Cancer is currently for Research Use Only (RUO) and for Performance Studies Only (PSO) in all market areas.

Lymph Node Metastasis

Aiforia® Lymph Node Metastasis
aiforia-lymph-node-metastasis

Supports the detection and quantification of metastases of breast cancer, melanoma, and colorectal cancer in lymph nodes from whole slide images.

Clinical performance highlights: 
  • Showed excellent correlation with visual diagnosis
  • Saved time (up to 40% faster)

 

Aiforia® Lymph Node Metastasis is currently for Research Use Only (RUO) and for Performance Studies Only (PSO) in all market areas.

 

Lymph Node Metastasis

Aiforia® Lymph Node Metastasis

aiforia-lymph-node-metastasis

Supports the detection and quantification of metastases of breast cancer, melanoma, and colorectal cancer in lymph nodes from whole slide images.

Clinical performance highlights: 
  • Showed excellent correlation with visual diagnosis
  • Saved time (up to 40% faster)

 

Aiforia® Lymph Node Metastasis is currently for Research Use Only (RUO) and for Performance Studies Only (PSO) in all market areas.

 

Elevate diagnostic capabilities with Aiforia® Clinical Suites

ic_discover_pink

Complete AI-driven workflow

Aiforia’s solutions support the complete AI-driven workflow through an optimized combination of the worklist, interactive Clinical Viewer, a broad portfolio of quantitative AI models, and case-level reporting.

ic_wellbeing_pink

Comprehensive case-level review and reporting

Aiforia® Clinical Suites conveniently combine results from multiple AI models, WSIs, and stainings into a case-level view and report for first-read diagnostic support.

ic_our_ai-1_pink

Precise, transparent AI results

Aiforia takes accuracy beyond standard AI heatmaps by clearly marking the exact findings with detailed visual overlays directly on the digital slides, enabling easy visual confirmation at any magnification level. This approach empowers pathologists with both visual transparency and exact quantitative data, delivering actionable insights.

ic_automate-2_pink

Seamless integrations & flexible deployment

Aiforia offers seamless integration into existing laboratory systems, with publicly available API specifications. Customers can choose from different deployment options according to their needs. 

Aiforia® Clinical Suites: Al-powered digital pathology workflow

The benefits of AI in clinical diagnostics

 
Increased efficiency
Increased efficiency

Diagnose more patients in less time by unbinding yourself from time-consuming, manual tasks.

 

Advanced precision
Advanced precision

Improve diagnostic accuracy and be confident in your decision-making.

 

Improved consistency
Improved consistency

Reduce variability to standardize your sample review and ensure democratized patient care.

 

Statement on Security

Aiforia Technologies holds information security to the highest standard. We hold several globally relevant quality and security certifications, so you can be sure your sensitive information is safe.

 

Learn more
Case studies, resources and more

AI for clinical diagnostics

PD-L1_stock 1_resource_carousel_banner

WEBINAR

PD-L1 on the edge: cut-offs, cognitive bias & the case for AI in lung cancer pathology

This webinar takes you inside the real-world diagnostic pressure points of PD-L1 TPS testing in NSCLC. With insights drawn from clinical research, pathology practice, and oncology decision-making, we examine the human limits of PD-L1 scoring and how AI can sharpen clinical decisions.

Register >

How did the Mayo Clinic choose a vendor for AI in pathology – carousel

BLOG POST

How did the Mayo Clinic choose a vendor for AI in pathology?

What to consider when choosing a vendor for AI in pathology? Learn how the Mayo Clinic evaluated platform providers based on six key criteria.

Read the article >

Digital pathology deployment in Veneto 8 steps to success_blog banner-1-1

BLOG POST

Digital pathology deployment in Veneto: 8 steps to success

What is required for pathology laboratories to go fully digital? Learn how the broadest public healthcare provider in the Veneto region did it.

Read the article >

Generic bg - AI duplicate-1

BLOG POST

5 reasons to use AI in clinical diagnostics

What additional benefit does AI bring to the digitized pathology workflow in clinical diagnostics? Read our article to find out.

Read the article >

prostate_grading_after

INTERVIEW

Benefits of AI and digital pathology to the clinical lab

Clinical pathologists, Dr. Kevin Sandeman and Dr. Tuomas Mirtti, discuss the impact and benefits of AI and digital pathology in clinical diagnostics.

Read the article >

 

Seeing is believing

Request a demo

Discover the power of AI for image analysis

Find out how to enhance your image analysis work in diagnostic pathology, preclinical studies, or medical research. The demo will be tailored based on your interests.

The demo will help you understand: 

  • How AI-assisted image analysis can increase efficiency, precision, and consistency in the pathology workflow.
  • The limitless possibilities Aiforia® Platform offers – both for research and clinical diagnostics – and the suitable use cases for your needs. 

We can either demonstrate Aiforia’s image analysis solutions on your own images or any of our 400+ application examples (i.e., neuron quantification, automated tumor grading, NASH analysis, etc.).

Fill in the form, and one of our experts will contact you shortly to schedule the time.
Regulatory note: Only certain Aiforia® Clinical AI models and the Aiforia® Clinical Suite Viewer are CE-IVD marked for diagnostic use in EU and EEA countries. In all other countries, the use is limited to Research Use Only, not for use in diagnostic procedures. Refer to the product information of each AI model for the regulatory status.